Ferro Beatriz E, Srivastava Shashikant, Deshpande Devyani, Pasipanodya Jotam G, van Soolingen Dick, Mouton Johan W, van Ingen Jakko, Gumbo Tawanda
Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands.
Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas, USA.
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6374-6. doi: 10.1128/AAC.00990-16. Print 2016 Oct.
In a hollow-fiber model, we mimicked the drug exposures achieved in the lungs of humans treated with standard amikacin, clarithromycin, and cefoxitin combination therapy for Mycobacterium abscessus infection. At optimal dosing, a kill rate of -0.09 (95% confidence interval, -0.04 to 0.03) log10 CFU per ml/day was achieved over the first 14 days, after which there was regrowth due to acquired drug resistance. Thus, the standard regimen quickly failed. A new regimen is needed.
在中空纤维模型中，我们模拟了用标准阿米卡星、克拉霉素和头孢西丁联合疗法治疗脓肿分枝杆菌感染的人类肺部所达到的药物暴露情况。在最佳给药剂量下，最初14天内实现了每毫升每天-0.09（95%置信区间，-0.04至0.03）log10 CFU的杀灭率，此后由于获得性耐药而出现细菌再生长。因此，标准治疗方案很快就失败了。需要一种新的治疗方案。
